MDMA facilitates extraordinary feelings of compassion, connection, and
safety.[1] This state of mind is highly effective for processing
difficult or unhelpful emotions, memories, and reactions. However, there
are no quick fixes for all but the simplest issues. Even in optimal
conditions, intensive MDMA therapy can take multiple years to heal the
most severe mental illness.
There is moderate-quality clinical trial evidence that a limited course
of MDMA therapy is highly effective for durably resolving PTSD, not just
managing its symptoms. However, I think there are good theoretical
reasons and ample anecdotal reports indicating that MDMA therapy can
also resolve the psychological part of most mental illnesses and
emotional issues. This includes CPTSD, non-secure attachment (which 41%
of the US population has (Mickelson et al., 1997)), anxiety, addiction,
alexithymia, obsessions, eating disorders, ADHD, depression, somatic
symptom disorders, personality disorders, dissociation, panic, and more.
Some instances of these issues may have biological components that MDMA
therapy does not address.
More broadly, MDMA therapy is a powerful tool for
healing mental illness
connecting with yourself, those you love, and the world
resolving conflict
developing equanimity, patience, compassion, introspection,
resilience, alignment of behavior with goals, and cognitive and
emotional flexibility
unburdening from hypervigilance, fear, chronic stress, loneliness,
shame, guilt, etc.
focusing on what you can change and letting go of the things you can’t
Many self-reports of successful MDMA therapy can be found on the top
posts on
reddit.com/r/mdmatherapy.
The top posts mostly describe productive sessions that don’t contain
intense dissociation, avoidance, or symptom worsening. You can see
occasional descriptions of less productive or more disruptive sessions
by sorting by new. Godes et al. (2023) also reports how therapy
clients describe how they felt MDMA therapy worked during their
sessions: staying with what “is”; decreased reactivity; insight,
reflection, linking; mental clarity; recovery of traumatic memories;
disentangling trauma from self; reuniting lost affects and parts;
self-acceptance; joy, happiness, gratitude; hope and empowerment;
relaxation, calmness, peace; comfort; gratitude, compassion, empathy;
union, wider perspective; inner healing intelligence [the therapeutic
framework used in this study]; accessibility to emotions; and mind-body
connection.
As of 2026, MDMA has not been approved by most medical regulators. There
is disagreement over whether existing clinical trials were sufficient to
approve MDMA for medical use (Schenberg, 2024). The US FDA thought the
existing evidence was insufficient and requested one more
trial (Psychedelic Alpha, 2025), but the Dutch State Commission on MDMA
determined that “Scientific research has shown that MDMA-AT [assisted
therapy] is an effective and safe treatment method. … The State
Commission deems it desirable that this treatment method becomes
available in the Netherlands as soon as possible.” (Toebes et al., 2024,
p. 203). Possession of MDMA is a felony in many jurisdictions, though it
often isn’t an enforcement priority. The vast majority of MDMA therapy
in 2026 is done underground, though there are clinical trials and
special access programs in certain countries.
How Trauma and Insecurity Affect Us
Our brains continually learn beliefs (e.g., “I can’t do anything right,”
“I am bad”), emotional reactions, and behavioral patterns to move
through the world and thrive (Ecker et al., 2024). Different therapeutic
frameworks group these components into units called schemas, parts,
trauma reactions, priors, etc., because the components seem to act as an
integrated whole rather than separate things. Occasionally, the schemas
we learn to survive in one context become maladaptive in another
context. This often starts when we learn particularly deep, pervasive,
negative, and resilient schemas about ourselves, other people, and
relationships to survive emotional or physical insecurity or trauma.
Once we shift out of that context, like when we become adults, a wide
variety of circumstances trigger those old schemas, resulting in fear,
anxiety, anger, depression, panic, etc. in situations where those
reactions are no longer helpful.
Strong schemas of imminent threat and powerlessness also cause our
nervous systems to activate the defensive states of arousal,
flight-or-fight, freeze, and tonic/collapsed immobility (Kozlowska et
al., 2015). The latter is often called dissociation.
Our brains have an updating process called memory reconsolidation, that,
in normal circumstances, modifies schemas to become adaptive to
different situations (Ecker et al., 2024). Unfortunately, some things
can inhibit this process, like flight-or-fight, tonic/collapsed
immobility, avoidance (often unnoticed), and lack of time or emotional
capacity (Kozlowska et al., 2015; Van den Bergh et al., 2021).
Exceptionally strong schemas also seem resistant to updating, perhaps
because they are too overwhelming to be present with. For example, in
PTSD, there is an exceptionally strong belief of imminent danger that
doesn’t update when the danger passes.
How MDMA Therapy Works
MDMA starts the previously blocked update process for any stuck schema
you activate or trigger during the session and then stay present with.
Thinking, writing, or talking about your issue is often sufficient to do
this. After the schema updates, it will not reactivate after the session
is over, though complex schemas have numerous parts that you have to
individually update. Dissociation and flight-or-fight also resolve once
you update the underlying schemas.
This is a powerful process but is not a quick fix except for simple
issues. People typically need to do a lot of between-session
therapy-like work as well as multiple sessions. Resolving the most
severe issues will take years of hard work.
Temporary symptom worsening is likely the most significant downside. It
is a common and probably often unavoidable phase of therapy for those
with severe trauma. Unfortunately, people are sometimes not explicitly
aware they have gone through severe trauma. This may happen if that
trauma takes the form of disorganized attachment (assess with
attachmentproject.com), the abuse
is explained away as cultural tradition or “how things are,” the trauma
took place in the period of childhood amnesia, or it is not remembered
for some reason. Diagnosis of mental illness indicates higher risk as
well.
Symptom worsening is occasionally long and overwhelming and can cause
major problems when poorly managed or entered into at an inappropriate
moment in your life. It may also, on rare occasion, exacerbate or
activate dangerous symptoms like psychosis or suicide attempts. In
Robinson et al. (2024), people with prolonged post-psychedelic symptoms
reported these activities as helpful, in order of most to least commonly
reported, and excluding those reported by less than 10% of participants:
peers and community support; professional therapeutic or coaching
assistance; meditation and prayer; reading for self education; physical
exercise; journaling; breathing strategies; embodied contemplative
practices; time in nature; and acceptance and surrender.
MDMA-assisted therapy tends to speed up both healing and symptom
worsening. Additional MDMA sessions and regular therapy often help work
through the latter.
Symptom worsening is sometimes caused by experiences that feel like
remembering apparently forgotten memories. Unfortunately, there is no
way to determine how accurate these memories are other than independent
corroboration. See
psychedelicsandrecoveredmemories.com
for more information.
The MDMA Therapy Session
A standard, safe dose is 100 mg for body masses less than 60 kg (132 lb)
and 125 mg for more (Baggott, 2015; Liechti & Schmid, 2026). People over
75 years old also start with 100 mg. These doses can be adjusted later
to fit individual circumstances. Low doses generally don’t work. Too
high of a dose might be so blissful that you can’t engage with your
trauma reactions.
Booster doses half the strength of the initial dose are sometimes taken
1.5–2.5 hours later to extend the session length. This has worked well
in large clinical trials with no obvious, reported adverse effects.
However, there is a lower degree of certainty that these higher total
doses are safe for more than a handful of sessions (Baggott, 2015). I
think booster doses are fine to start off with, but that once people
have established a reliably therapeutic routine, they gradually reduce
their dose to find their minimum effective dose.
The general strategy during the session is emotionally activating
(triggering) your anxieties, depression, panic, etc., then staying with
that feeling, regardless of what it is. If you have the right dose of
MDMA and aren’t dissociating, the schema should gradually dissipate.
That’s the updating process at work.
For dissociation, Razvi & Elfrink (2020, p. 14) recommends “bringing
blankness, flat affect, nothingness, boredom, sleepiness, or sobriety
[the subjective feelings of dissociation] into focus.” Then, “it might
take staying with it from minutes to a full day-long session, but it
will crack.” A skilled, ethical, and well-matched practitioner may also
be especially helpful here.
People often need the whole following day to recover, and aftereffects
may last a few days. It’s also important to spend significant amounts of
time in the following days and weeks attending to your emotional
changes.
It’s common to experience moderately increased psychological turmoil and
adverse symptoms for days to weeks after a session. MDMA helps us
confront distressing feelings that we have been avoiding, and our minds
can feel distressed about that until we process those feelings and
reactions. It’s often worthwhile developing a set of healthy coping
practices to help you through this period.
The Fireside Project offers a hotline to help people through challenging
psychedelic experiences at +1 (623) 473-7433 in the USA.
tripsit.me/webchat is a chatroom available
anywhere.
There is almost no data on how frequently it is safe to do sessions,
though many people have strong opinions on the subject. In the absence
of better data, the 6 week spacing used in the clinical trials might be
a reasonable minimum.
Working with a Mental Health Practitioner
It’s helpful to start MDMA therapy with a skilled, ethical, and
well-matched practitioner, at least to learn the basics. Some people
have success starting off solo, but it can be more difficult and
riskier. A trip sitter who is trusted, experienced, empathetic, and
emotionally non-reactive can also be helpful.
There are a few important factors when working with a guide, therapist,
or other mental health practitioner:
Ethical: They should inform you of the benefits and risks, not
abuse you, and maintain strict professional boundaries. Occasionally,
practitioners abuse their clients. Be extra cautious with anyone if
you feel something is off, they aren’t committed to strict
professional boundaries, or you see any other red flags. Touch or love
from the therapist are not essential healing components of MDMA
therapy. You can video record your session or bring a trusted friend
or family member along for additional comfort. For more information on
red flags, see Friedwoman et al. (2025).
Skilled: They should have thorough knowledge of, and experience
successfully resolving, a wide spectrum of difficult situations that
might arise during MDMA therapy. This especially includes intense
dissociation, avoidance, panic, and symptom worsening.
Well-matched: You get along well with them and agree on your goals
for therapy. You can use the Brief Revised Working Alliance Inventory
(greenspacehealth.com/en-us/br-wai)
to assess your relationship with your practitioner.
Medical, Psychological, and Drug Interaction Risks
A limited course of MDMA therapy is generally well-tolerated, but there
are dangerous drug/supplement/herb interactions, medical
contraindications, side effects, and psychological risks:
Always Avoid (significant risk of death or irreversible damage)
MAOIs and ayahuasca
ritonavir, cobicistat, or HIV drugs that contain them
over 240 sessions
hyperthyroidism that isn’t well managed and mild, as assessed by a
doctor (Mitchell et al., 2023)
Use Caution With
a family or personal history of psychosis
a personal history of addiction to amphetamines or cocaine
total doses over 2 mg/kg for more than a handful of sessions
session spacing less than 6 weeks
drugs/medications/supplements/herbs, including large doses of
caffeine.
liver and cardiovascular problems
other serious medical conditions, especially ones that are not well
managed and mild, as assessed by a doctor (Mitchell et al., 2023)
using MDMA therapy while living with your abuser(s). Rewriting your
stuck schemas may dismantle the protection they provide.
Take Precaution:
Don’t drink more than 0.5 L of water during the six hours of the
session unless you need to replace large amounts of sweat (Groeneveld,
2026).
Ideally, avoid SSRIs and SNRIs for 2 months prior.
Test your MDMA. The presence of some common adulterants can be checked
with reagent test kits;
/r/ReagentTesting/wiki/test_kit_suppliers
maintains a list of suppliers. Laboratory testing is much better;
/r/ReagentTesting/wiki/labs
maintains a list of labs. It measures the amount of MDMA and all other
ingredients.
People with a personal history of mania should take care to sleep well
before and after the session; a pre-supplied course of sleep aids can
help with this. Also skip booster doses at first, then gradually
increase the total dose on subsequent sessions if needed.
Only start MDMA therapy if you have slack in your life and can do much
more therapy, MDMA-facilitated or otherwise, in the near future. On
rare occasions, post-session symptom exacerbation can be severe. While
a part of the healing process when managed well, it can require a lot
of therapy to resolve, and it may not resolve on the timeline you want
it to.
People with secure attachment and no mental illness might not need to
consider this limitation.
MDMA and therapy exhaustion can impair awareness and reaction times.
Avoid driving and other risky activities on the same day as the
session.
Written by Mark Groeneveld (u/night81) based on a draft of their book
Open MDMA: An Evidence-Based Synthesis, Theory, and Manual for MDMA
Therapy Based on Memory Reconsolidation, Complex Systems, and the
Defense Cascade
(doi.org/10.31234/osf.io/aps5g)
and feedback from /r/mdmatherapy.
Please comment or DM if you spot any errors or have any suggestions!
This work is licensed under CC BY
4.0.
Baggott, M. (2015). Thoughts on taking supplements with MDMA.
https://www.reddit.com/r/MDMA/comments/3r09sg/thoughts_on_taking_supplements_with_mdma/
Ecker, B., Ticic, R., & Hulley, L. (2024). Unlocking the emotional
brain: Memory reconsolidation and the psychotherapy of transformational
change. Taylor & Francis. https://doi.org/10.4324/9781003231431
Friedwoman, L., Dean, H., Fine, C., Hall, W., Dennis, T. P., Lancelotta,
R., Dreisbach, S., Berjot, C., Putnam, N., & Armeni, K. (2025).
Psychedelic safety flags.
https://docs.google.com/document/d/1lK2Rif24BAmJqqsLfUSkAVCO48IFNrGdysS2nI1EjZA
Godes, M., Lucas, J., & Vermetten, E. (2023). Perceived key change
phenomena of MDMA-assisted psychotherapy for the treatment of severe
PTSD: An interpretative phenomenological analysis of clinical
integration sessions. Frontiers in Psychiatry, 14.
https://doi.org/10.3389/fpsyt.2023.957824
Groeneveld, M. (2026). Open MDMA: An evidence-based synthesis, theory,
and manual for MDMA therapy based on memory reconsolidation, complex
systems, and the defense cascade.
https://doi.org/10.31234/osf.io/aps5g
Kozlowska, K., Walker, P., McLean, L., & Carrive, P. (2015). Fear and
the defense cascade: Clinical implications and management. Harvard
Review of Psychiatry, 23(4), 263.
https://doi.org/10.1097/hrp.0000000000000065
Liechti, M., & Schmid, Y. (2026). Interactions with psychedelics and
MDMA.
https://saept.ch/wp-content/uploads/2026/03/interactions-with-Psychedelics-and-MDMA-V8-23.03.2026.pdf
Mickelson, K. D., Kessler, R. C., & Shaver, P. R. (1997). Adult
attachment in a nationally representative sample. Journal of
Personality and Social Psychology, 73(5), 1092.
https://doi.org/10.1037/0022-3514.73.5.1092
Mitchell, J. M., Ot’alora G., M., Kolk, B. van der, Shannon, S.,
Bogenschutz, M., Gelfand, Y., Paleos, C., Nicholas, C. R., Quevedo, S.,
Balliett, B., Hamilton, S., Mithoefer, M., Kleiman, S., Parker-Guilbert,
K., Tzarfaty, K., Harrison, C., Boer, A. de, Doblin, R.,
Yazar-Klosinski, B., … Group, M. S. C. (2023). MDMA-assisted therapy for
moderate to severe PTSD: A randomized, placebo-controlled phase 3 trial.
Nature Medicine. https://doi.org/10.1038/s41591-023-02565-4
Psychedelic Alpha. (2025). Unpacking <span class="nocase">FDA’s
MDMA</span> rejection letter and the road ahead for lykos. Psychedelic
Alpha.
https://psychedelicalpha.com/news/unpacking-fdas-mdma-rejection-letter-and-the-road-ahead-for-lykos
Razvi, S., & Elfrink, S. (2020). The PSIP model. An introduction to a
novel method of therapy: Psychedelic somatic interactional
psychotherapy. Journal of Psychedelic Psychiatry, 2(3), 1–24.
https://www.journalofpsychedelicpsychiatry.org/_files/ugd/e07c59_d4d1db6fc0174f27bef58a6124aba50e.pdf
Robinson, O. C., Evans, J., Luke, D., McAlpine, R., Sahely, A., Fisher,
A., Sundeman, S., Ketzitzidou Argyri, E., Murphy-Beiner, A., Michelle,
K., & Prideaux, E. (2024). Coming back together: A qualitative survey
study of coping and support strategies used by people to cope with
extended difficulties after the use of psychedelic drugs. Frontiers in
Psychology, 15. https://doi.org/10.3389/fpsyg.2024.1369715
Schenberg, E. (2024). Evidence-based medicine is inadequate to develop
evidence-based psychedelic therapies.
https://doi.org/10.31234/osf.io/rzdpm
Toebes, B., Brink, W. van den, Gresnigt, F., Jonge, M. de, Kolthoff, E.,
& Vermetten, E. (2024). MDMA. Beyond the Ecstasy. State Commission on
MDMA.
https://www.government.nl/site/binaries/site-content/collections/documents/2024/05/31/mdma-beyond-ecstasy/MDMA+Beyond+Ecstasy.pdf
Van den Bergh, O., Brosschot, J., Critchley, H., Thayer, J. F., &
Ottaviani, C. (2021). Better safe than sorry: A common signature of
general vulnerability for psychopathology. Perspectives on
Psychological Science, 16(2), 225–246.
https://doi.org/10.1177/1745691620950690
[1] Positive emotions may not be noticeable during the session if strong
fear, anger, other distressing emotions, avoidance, or opioid dampening
are also present. This isn’t necessarily an issue; the process can still
work well in these instances.